Deciphera Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCPH research report →
Companywww.deciphera.com
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
- CEO
- Steven L. Hoerter
- IPO
- 2017
- Employees
- 355
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $2.21B
- P/E
- -11.17
- P/S
- 13.55
- P/B
- 6.20
- EV/EBITDA
- -10.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.72%
- Op Margin
- -129.14%
- Net Margin
- -119.34%
- ROE
- -56.29%
- ROIC
- -55.99%
Growth & Income
- Revenue
- $163.36M · 21.87%
- Net Income
- $-194,942,000 · -8.95%
- EPS
- $-2.29 · 3.38%
- Op Income
- $-210,958,000
- FCF YoY
- 4.05%
Performance & Tape
- 52W High
- $25.61
- 52W Low
- $9.90
- 50D MA
- $21.07
- 200D MA
- $15.75
- Beta
- 0.18
- Avg Volume
- 1.86M
Get TickerSpark's AI analysis on DCPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 24 | Brightstar Associates LLC | other | 48,136 |
| Apr 22, 24 | Brightstar Associates LLC | other | 48,136 |
| Feb 15, 24 | Sherman Matthew L | other | 17,275 |
| Feb 16, 24 | Sherman Matthew L | sell | 2,615 |
| Feb 15, 24 | Sherman Matthew L | other | 69,100 |
| Feb 15, 24 | Kelly Thomas Patrick | other | 17,275 |
| Feb 16, 24 | Kelly Thomas Patrick | sell | 3,010 |
| Feb 15, 24 | Kelly Thomas Patrick | other | 69,100 |
| Feb 15, 24 | Pitman Jama | other | 10,000 |
| Feb 16, 24 | Pitman Jama | sell | 2,267 |
Our DCPH Coverage
We haven't published any research on DCPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DCPH Report →